LLY

1,014.1

-1.68%↓

JNJ

240.68

+0.23%↑

ABBV

220

-2.15%↓

NVS

159.69

+0.31%↑

MRK

118.72

+1.06%↑

LLY

1,014.1

-1.68%↓

JNJ

240.68

+0.23%↑

ABBV

220

-2.15%↓

NVS

159.69

+0.31%↑

MRK

118.72

+1.06%↑

LLY

1,014.1

-1.68%↓

JNJ

240.68

+0.23%↑

ABBV

220

-2.15%↓

NVS

159.69

+0.31%↑

MRK

118.72

+1.06%↑

LLY

1,014.1

-1.68%↓

JNJ

240.68

+0.23%↑

ABBV

220

-2.15%↓

NVS

159.69

+0.31%↑

MRK

118.72

+1.06%↑

LLY

1,014.1

-1.68%↓

JNJ

240.68

+0.23%↑

ABBV

220

-2.15%↓

NVS

159.69

+0.31%↑

MRK

118.72

+1.06%↑

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Avatud

SektorTervishoid

1.33 1.53

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.27

Max

1.33

Põhinäitajad
By Trading Economics
Sissetulek	-16M -13M
Müük	-15M 14M
Kasumimarginaal	-90.037
Töötajad	103
EBITDA	-16M -10M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+235.83% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. märts 2026

Turustatistika
By TradingEconomics
Turukapital	7.2M 501M
Eelmine avamishind	-0.2
Eelmine sulgemishind	1.33

Uudiste sentiment

By Acuity

50%

149 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. veebr 2026, 23:26 UTC

Suurimad hinnamuutused turgudel

Moderna Stock Slips After FDA Refuses Flu Vaccine Review

10. veebr 2026, 22:31 UTC

Tulu

Correction to America Movil 4Q Profit Article

10. veebr 2026, 22:22 UTC

Tulu

America Movil 4Q Profit Jumps on Lower Financial Costs

10. veebr 2026, 23:51 UTC

Market Talk

Tulu

Commonwealth Bank's Margin Management Gives It a Platform -- Market Talk

10. veebr 2026, 23:42 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

10. veebr 2026, 23:40 UTC

Market Talk

Tulu

Commonwealth Bank Bear Says 1H Result Looks Strong -- Market Talk

10. veebr 2026, 23:21 UTC

Market Talk

Ford Says EV Shift Was Driven by Demand Changes -- Market Talk

10. veebr 2026, 23:21 UTC

Market Talk

Global Equities Roundup: Market Talk

10. veebr 2026, 22:17 UTC

Market Talk

Australia's One Nation Now Commands Working Class Vote -- Market Talk

10. veebr 2026, 22:15 UTC

Tulu

Humana Earnings Will Shed More Light on Medicare Prospects -- Barrons.com

10. veebr 2026, 22:10 UTC

Tulu

Intact Financial 4Q Book Value Per Share Was C$107.35 >IFC.T

10. veebr 2026, 22:10 UTC

Tulu

Intact Financial Raises Qtr Dividend to C$1.47 >IFC.T

10. veebr 2026, 22:09 UTC

Tulu

Intact Financial 4Q Combined Ratio Was 85.9% >IFC.T

10. veebr 2026, 22:09 UTC

Tulu

Intact Financial 4Q Adj EPS C$5.50 >IFC.T

10. veebr 2026, 22:01 UTC

Tulu

Intact Financial 4Q EPS C$5.24 >IFC.T

10. veebr 2026, 21:54 UTC

Tulu

James Hardie Industries Sees FY26 Total Adjusted EBITDA $1.232B to $1.263B >JHX

10. veebr 2026, 21:53 UTC

Tulu

Robinhood Stock Tumbles as Crypto-Related Revenue Falls Short of Expectations -- Barrons.com

10. veebr 2026, 21:51 UTC

Tulu

James Hardie Industries Sees FY26 Free Cash Flow at Least $200M

10. veebr 2026, 21:51 UTC

Tulu

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10. veebr 2026, 21:51 UTC

Tulu

James Hardie Industries: Focused on the Achievement of $125 M Target >JHX

10. veebr 2026, 21:51 UTC

Tulu

James Hardie Industries: Integration and Cost Synergies Ahead of Schedule >JHX

10. veebr 2026, 21:51 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Evolution Net Debt A$362 Million at Dec. 31 Vs A$1.29 Billion Year Earlier

10. veebr 2026, 21:50 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Evolution: Gearing 6% at Dec. 31, From 23% a Year Earlier

10. veebr 2026, 21:50 UTC

Tulu

James Hardie Industries 3Q EPS 12c >JHX

10. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10. veebr 2026, 21:50 UTC

Tulu

James Hardie Industries 3Q Adj EPS 24c >JHX

10. veebr 2026, 21:49 UTC

Tulu

James Hardie Industries 3Q Sales $1.24B >JHX

10. veebr 2026, 21:49 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Evolution 1H Operating Mine Cash Flow a Record A$1.73 Billion

10. veebr 2026, 21:48 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Evolution 1H Ebitda A$1.56 Billion, Up 59% On-Year

10. veebr 2026, 21:47 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Evolution 1H Revenue A$2.79 Billion, Up 37% On-Year

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

235.83% tõus

12 kuu keskmine prognoos

Keskmine 4.03 USD 235.83%

Kõrge 6 USD

Madal 2.1 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

149 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.